Compare Stocks: NRIX, PRAX, NUVL, and KRYS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$335.73 +1.0%	$345.06	$136.73 ▼ $382.54	$9.83B	0.53	576,677 shs	255,127 shs
NRIX Nurix Therapeutics	$27.17 +0.4%	$22.56	$8.19 ▼ $27.35	$2.81B	1.79	1.04 million shs	1.15 million shs
NUVL Nuvalent	$123.96	$123.76	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
PRAX Praxis Precision Medicines	$376.38 +2.6%	$315.82	$37.19 ▼ $391.64	$10.24B	2.78	405,899 shs	581,487 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	+1.04%	+1.25%	-5.39%	+14.47%	+123.42%
NRIX Nurix Therapeutics	+0.44%	+4.98%	+17.52%	+78.28%	+156.81%
NUVL Nuvalent	0.00%	0.00%	0.00%	+22.73%	+63.02%
PRAX Praxis Precision Medicines	+2.61%	+2.57%	+19.71%	+17.39%	+699.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRYS Krystal Biotech	$335.73 +1.0%	$345.06	$136.73 ▼ $382.54	$9.83B	0.53	576,677 shs	255,127 shs
NRIX Nurix Therapeutics	$27.17 +0.4%	$22.56	$8.19 ▼ $27.35	$2.81B	1.79	1.04 million shs	1.15 million shs
NUVL Nuvalent	$123.96	$123.76	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
PRAX Praxis Precision Medicines	$376.38 +2.6%	$315.82	$37.19 ▼ $391.64	$10.24B	2.78	405,899 shs	581,487 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRYS Krystal Biotech	+1.04%	+1.25%	-5.39%	+14.47%	+123.42%
NRIX Nurix Therapeutics	+0.44%	+4.98%	+17.52%	+78.28%	+156.81%
NUVL Nuvalent	0.00%	0.00%	0.00%	+22.73%	+63.02%
PRAX Praxis Precision Medicines	+2.61%	+2.57%	+19.71%	+17.39%	+699.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	8.84% Upside
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.21	25.93% Upside
NUVL Nuvalent	2.15	Hold	$127.73	3.04% Upside
PRAX Praxis Precision Medicines	3.00	Buy	$579.55	53.98% Upside

Current Analyst Ratings Breakdown

Latest NRIX, PRAX, NUVL, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/10/2026	NRIX Nurix Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$33.00 ➝ $36.00
8/7/2026	PRAX Praxis Precision Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$449.00 ➝ $462.00
8/7/2026	PRAX Praxis Precision Medicines	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$514.00
8/7/2026	PRAX Praxis Precision Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive	$323.00 ➝ $362.00
8/6/2026	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$575.00 ➝ $582.00
8/4/2026	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$378.00 ➝ $386.00
8/4/2026	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
8/3/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRYS Krystal Biotech	$440.48M	22.56	$7.37 per share	45.58	$42.06 per share	7.98
NRIX Nurix Therapeutics	$36.77M	76.69	N/A	N/A	$5.29 per share	5.14
NUVL Nuvalent	N/A	N/A	N/A	N/A	$15.95 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	1,229.07	N/A	N/A	$34.85 per share	10.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRYS Krystal Biotech	$204.83M	$7.98	42.07	35.98	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)
NUVL Nuvalent	-$425.38M	-$6.06	N/A	N/A	N/A	N/A	-40.11%	-35.43%	N/A
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/4/2026 (Estimated)

Latest NRIX, PRAX, NUVL, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRYS Krystal Biotech	N/A	8.32	7.96
NRIX Nurix Therapeutics	N/A	6.34	6.34
NUVL Nuvalent	N/A	16.14	16.14
PRAX Praxis Precision Medicines	N/A	15.73	15.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRYS Krystal Biotech	86.29%
NRIX Nurix Therapeutics	N/A
NUVL Nuvalent	97.26%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
KRYS Krystal Biotech	13.10%
NRIX Nurix Therapeutics	6.70%
NUVL Nuvalent	5.02%
PRAX Praxis Precision Medicines	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable
NUVL Nuvalent	40	79.00 million	75.03 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable

NRIX, PRAX, NUVL, and KRYS Headlines

Recent News About These Companies

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Should You Buy?

2 hours ago | americanbankingnews.com

Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High - What's Next?

2 hours ago | marketbeat.com

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

August 17 at 12:50 AM | finance.yahoo.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% Higher - Still a Buy?

August 17 at 1:39 PM | marketbeat.com

9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB

August 16 at 3:43 AM | marketbeat.com

HC Wainwright Has Bullish Forecast for PRAX Q3 Earnings

August 13, 2026 | americanbankingnews.com

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why

August 12, 2026 | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

August 11, 2026 | theglobeandmail.com

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

August 11, 2026 | zacks.com

Equities Analysts Offer Predictions for PRAX Q3 Earnings

August 11, 2026 | marketbeat.com

Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX

August 10, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $582.00

August 9, 2026 | americanbankingnews.com

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

August 8, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Charles River Labs (CRL) and Senseonics Holdings (SENS)

August 8, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), BioCryst (BCRX) and GH Research (GHRS)

August 8, 2026 | theglobeandmail.com

Praxis Precision Medicines (NASDAQ:PRAX) Raised to Hold at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating

August 8, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week High After Strong Earnings

August 8, 2026 | americanbankingnews.com

Praxis signals two FDA decisions in ~six months, targets ~$10B ulixacaltamide peak sales while building a ~300-person field force

August 7, 2026 | seekingalpha.com

Praxis: Commercial Launch Could Smash Expectations (Video)

August 7, 2026 | seekingalpha.com

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX, PRAX, NUVL, and KRYS Company Descriptions

Krystal Biotech NASDAQ:KRYS

$335.73 +3.46 (+1.04%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$338.76 +3.02 (+0.90%)

As of 04:03 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Nurix Therapeutics NASDAQ:NRIX

$27.17 +0.12 (+0.44%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$27.18 +0.01 (+0.04%)

As of 06:07 AM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Nuvalent NASDAQ:NUVL

$123.96 0.00 (0.00%)

As of 07/16/2026

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$376.38 +9.57 (+2.61%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$366.02 -10.37 (-2.75%)

As of 04:48 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRIX, PRAX, NUVL, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRIX, PRAX, NUVL, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRIX, PRAX, NUVL, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX, PRAX, NUVL, and KRYS Company Descriptions

Krystal Biotech NASDAQ:KRYS

Nurix Therapeutics NASDAQ:NRIX

Nuvalent NASDAQ:NUVL

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRIX, PRAX, NUVL, and KRYS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRIX, PRAX, NUVL, and KRYS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRIX, PRAX, NUVL, and KRYS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX, PRAX, NUVL, and KRYS Company Descriptions

Krystal Biotech NASDAQ:KRYS

Nurix Therapeutics NASDAQ:NRIX

Nuvalent NASDAQ:NUVL

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools